Abstract
Background: Epstein–Barr virus–positive nasopharyngeal carcinoma (EBV‐NPC) is highly prevalent in Asia. EBV IgA serologies (targeting viral capsid antigen [VCA] and early antigen [EA]) are commonly used for NPC screening in Singapore. However, the predictive value of longitudinal serologic trends in real‐world screening remains unclear. This study evaluated EBV IgA serologic patterns and their relationship with NPC development. Methods: We conducted a retrospective cohort study of 1977 asymptomatic individuals screened for NPC between 2008 and 2021 at a tertiary medical center in Singapore. Patients were predominantly Chinese (95%) and aged 12–90 years. Data on EBV IgA serologies (EA‐IgA and VCA‐IgA), plasma EBV DNA, nasoendoscopy, biopsies, and MRI findings were collected. Primary outcomes included EBV serologic trends (stratified into positive for only one serology type, non‐fluctuating positivity, fluctuating positivity, seroconversion or seroreversion) and incidence of NPC during follow‐up. Results: Of the 1977 patients, 62% tested positive for either EA‐IgA or VCA‐IgA. 7.2% showed stable positive titers, 5% had fluctuating titers, 2.4% seroconverted, and 23.5% seroreverted. Six patients (0.3%) developed NPC; all were Chinese, with a mean age of 50. Three had Stage I, one had Stage III, and two had Stage IV disease. Their serologic trajectories varied with no consistent pattern observed. Elevated EBV EA‐IgA (2/6) or VCA‐IgA (2/6) titers were observed 1–2 years before diagnosis. Conclusion: No consistent EBV serologic pattern preceded NPC diagnosis in this cohort. The low NPC detection rate of 0.3% suggests limited screening utility of EBV serologies in a heterogeneous, intermediate‐risk population.

This publication has 14 references indexed in Scilit: